Short-Course or Total Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer - Current Status and Future Perspectives

Huang, 2019, Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations, Gut., 68, 130, 10.1136/gutjnl-2017-314828

2021, NCCN Practice Guidelines in Oncology

Mavros, 2021, Clinical trials of systemic chemotherapy for resectable pancreatic cancer: a review, JAMA Surg., 156, 663, 10.1001/jamasurg.2021.0149

Conroy, 2018, FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer, N Engl J Med., 379, 2395, 10.1056/NEJMoa1809775

Bockhorn, 2014, Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS), Surgery., 155, 977, 10.1016/j.surg.2014.02.001

Neoptolemos, 2004, A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer, N Engl J Med., 350, 1200, 10.1056/NEJMoa032295

Neoptolemos, 2010, Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial, JAMA., 304, 1073, 10.1001/jama.2010.1275

Oettle, 2013, Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial, JAMA., 310, 1473, 10.1001/jama.2013.279201

Neoptolemos, 2017, Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial, Lancet., 389, 1011, 10.1016/S0140-6736(16)32409-6

van Dam, 2022, Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomised controlled trials, Eur J Cancer., 160, 140, 10.1016/j.ejca.2021.10.023

Lambert, 2019, An update on treatment options for pancreatic adenocarcinoma, Ther Adv Med Oncol., 11, 1758835919875568, 10.1177/1758835919875568

ClinicalTrials.gov identifier

ClinicalTrials.gov identifier

Labori, 2017, Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial, BMC Surg., 17, 94, 10.1186/s12893-017-0291-1

Schwarz, 2018, Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study), BMC Cancer., 18, 762, 10.1186/s12885-018-4663-4

Sohal, 2021, Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial, JAMA Oncol., 7, 421, 10.1001/jamaoncol.2020.7328

Ghaneh, 2020, ESPAC-5F: Four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer, J Clin Oncol., 38, 4505, 10.1200/JCO.2020.38.15_suppl.4505

Janssen, 2021, Total neoadjuvant FOLFIRINOX vs. neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial, BMC Cancer., 21, 300, 10.1186/s12885-021-08031-z

Versteijne, 2020, Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the dutch randomized phase III PREOPANC trial, J Clin Oncol., 38, 1763, 10.1200/JCO.19.02274

Unno, 2019, Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 vs. upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05), J Clin Oncol., 37, 189, 10.1200/JCO.2019.37.4_suppl.189

Motoi, 2019, Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05), Jpn J Clin Oncol., 49, 190, 10.1093/jjco/hyy190

Ettrich, 2018, Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group, BMC Cancer., 18, 1298, 10.1186/s12885-018-5183-y

Reni, 2018, Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial, Lancet Gastroenterol Hepatol., 3, 413, 10.1016/S2468-1253(18)30081-5

Kim, 2021, Total neoadjuvant therapy for operable pancreatic cancer, Ann Surg Oncol., 28, 2246, 10.1245/s10434-020-09149-3

Versteijne, 2022, Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the dutch randomized PREOPANC trial, J Clin Oncol., 10.1200/JCO.21.02233.

Janssen, 2021, Added value of radiotherapy following neoadjuvant FOLFIRINOX for resectable and borderline resectable pancreatic cancer: a systematic review and meta-analysis, Ann Surg Oncol., 28, 8297, 10.1245/s10434-021-10276-8

Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av pancreaskreft

Janssen, 2019, Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis, J Natl Cancer Inst., 111, 782, 10.1093/jnci/djz073

van Roessel, 2020, Evaluation of adjuvant chemotherapy in patients with resected pancreatic cancer after neoadjuvant FOLFIRINOX treatment, JAMA Oncol., 6, 1733, 10.1001/jamaoncol.2020.3537

Murphy, 2018, Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial, JAMA Oncol., 4, 963, 10.1001/jamaoncol.2018.0329

Datta, 2021, Association of total neoadjuvant therapy with major pathologic response and survival in localized pancreatic cancer: a multi-institutional analysis of 504 patients, J Clin Oncol., 39, 4145, 10.1200/JCO.2021.39.15_suppl.4145

Truty, 2021, Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline/locally advanced pancreatic cancer, Ann Surg., 273, 341, 10.1097/SLA.0000000000003284

Tzeng, 2012, Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy, Ann Surg Oncol., 19, 2045, 10.1245/s10434-011-2211-4

Labori, 2016, Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study, Acta Oncol., 55, 265, 10.3109/0284186X.2015.1068445

Groot, 2018, Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma, Ann Surg., 267, 936, 10.1097/SLA.0000000000002234

Alva-Ruiz, 2022, Neoadjuvant chemotherapy switch in borderline resectable/locally advanced pancreatic cancer, Ann Surg Oncol., 29, 1579, 10.1245/s10434-021-10991-2

van Roessel, 2021, Scoring of tumour response after neoadjuvant therapy in resected pancreatic cancer: systematic review, Br J Surg., 108, 119, 10.1093/bjs/znaa031

Perri, 2020, Response to preoperative therapy in localized pancreatic cancer, Front Oncol., 10, 516, 10.3389/fonc.2020.00516

Evans, 2015, Non-metastatic pancreatic cancer: resectable, borderline resectable, and locally advanced-definitions of increasing importance for the optimal delivery of multimodality therapy, Ann Surg Oncol., 22, 3409, 10.1245/s10434-015-4649-2

Perri, 2021, Radiographic and serologic predictors of pathologic major response to preoperative therapy for pancreatic cancer, Ann Surg., 273, 806, 10.1097/SLA.0000000000003442

Tsai, 2020, Importance of normalization of CA19-9 levels following neoadjuvant therapy in patients with localized pancreatic cancer, Ann Surg., 271, 740, 10.1097/SLA.0000000000003049

Ye, 2020, The prognostic value of CA19-9 response after neoadjuvant therapy in patients with pancreatic cancer: a systematic review and pooled analysis, Cancer Chemother Pharmacol., 86, 731, 10.1007/s00280-020-04165-2

Katz, 2012, Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators, Cancer., 118, 5749, 10.1002/cncr.27636

Perri, 2020, Response and survival associated with first-line FOLFIRINOX vs gemcitabine and nab-paclitaxel chemotherapy for localized pancreatic ductal adenocarcinoma, JAMA Surg., 155, 832, 10.1001/jamasurg.2020.2286

Panda, 2021, Borderline resectable and locally advanced pancreatic cancer: FDG PET/MRI and CT tumor metrics for assessment of pathologic response to neoadjuvant therapy and prediction of survival, Am J Roentgenol., 217, 730, 10.2214/AJR.20.24567

Lee, 2021, Metabolic activity by FDG-PET/CT after neoadjuvant chemotherapy in borderline resectable and locally advanced pancreatic cancer and association with survival, Br J Surg., 109, 61, 10.1093/bjs/znab229

Evangelista, 2021, The role of FDG PET/CT or PET/MRI in assessing response to neoadjuvant therapy for patients with borderline or resectable pancreatic cancer: a systematic literature review, Ann Nucl Med., 35, 767, 10.1007/s12149-021-01629-0

Kamarajah, 2021, Adjuvant chemotherapy associated with survival benefit following neoadjuvant chemotherapy and pancreatectomy for pancreatic ductal adenocarcinoma: a population-based cohort study, Ann Surg Oncol., 28, 6790, 10.1245/s10434-021-09823-0

Chantrill, 2015, Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial, Clin Cancer Res., 21, 2029, 10.1158/1078-0432.CCR-15-0426

Tiriac, 2018, Organoid profiling identifies common responders to chemotherapy in pancreatic cancer, Cancer Discov., 8, 1112, 10.1158/2159-8290.CD-18-0349

Heredia-Soto, 2021, Liquid biopsy in pancreatic cancer: are we ready to apply it in the clinical practice?, Cancers., 13, 1986, 10.3390/cancers13081986

Gemenetzis, 2018, Circulating tumor cells dynamics in pancreatic adenocarcinoma correlate with disease status: results of the prospective CLUSTER study, Ann Surg., 268, 408, 10.1097/SLA.0000000000002925

Bernard, 2019, Circulating nucleic acids are associated with outcomes of patients with pancreatic cancer, Gastroenterology., 156, 108, 10.1053/j.gastro.2018.09.022

Yin, 2021, Improved assessment of response status in patients with pancreatic cancer treated with neoadjuvant therapy using somatic mutations and liquid biopsy analysis, Clin Cancer Res., 27, 740, 10.1158/1078-0432.CCR-20-1746

Miyabayashi, 2021, Molecular and phenotypic profiling for precision medicine in pancreatic cancer: current advances and future perspectives, Front Oncol., 11, 682872, 10.3389/fonc.2021.682872

Pishvaian, 2020, Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial, Lancet Oncol., 21, 508, 10.1016/S1470-2045(20)30074-7

Mosele, 2020, Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group, Ann Oncol., 31, 1491, 10.1016/j.annonc.2020.07.014